PDF(Pubmed)
Abstract：
During the COVID-19 pandemic, several strategies were suggested for the management of the disease, including pharmacological and non-pharmacological treatments such as convalescent plasma (CP). The use of CP was suggested due to the beneficial results shown in treating other viral diseases.
To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.
To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.
摘要：
背景：在COVID-19大流行期间，提出了几种治疗疾病的策略，包括药理学和非药理学治疗，如恢复期血浆（CP）。由于在治疗其他病毒性疾病中显示的有益结果,建议使用CP。
目的：确定全血CP对COVID-19患者的疗效和安全性。
方法：在综合医院的COVID-19患者中进行试点临床试验。将受试者分为接受400mlCP（n=23）或400ml标准血浆（SP）（n=19）和未输注组（NT）（n=37）的三组。患者还接受了COVID-19的标准药物治疗。从入院到第21天，每天对受试者进行随访。
结果：CP没有改善COVID-19中度和重度变体的存活曲线，也没有降低COVID-19和SOFA临床进展量表评估的疾病严重程度。没有患者对CP有严重的输血后反应。
结论：CP治疗并不能降低患者的死亡率，即使其给药具有高度的安全性。
目的：确定全血CP对COVID-19患者的疗效和安全性。
方法：在综合医院的COVID-19患者中进行试点临床试验。将受试者分为接受400mlCP（n=23）或400ml标准血浆（SP）（n=19）和未输注组（NT）（n=37）的三组。患者还接受了COVID-19的标准药物治疗。从入院到第21天，每天对受试者进行随访。
结果：CP没有改善COVID-19中度和重度变体的存活曲线，也没有降低COVID-19和SOFA临床进展量表评估的疾病严重程度。没有患者对CP有严重的输血后反应。
结论：CP治疗并不能降低患者的死亡率，即使其给药具有高度的安全性。
